Contraindications of Vivelle-Dot®

Vivelle-Dot should not be used in women with any of the following conditions:

  • Undiagnosed abnormal genital bleeding
  • Known, suspected, or history of cancer of the breast
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis, pulmonary embolism, or a history of these conditions
  • Active or recent (eg, within the past year) arterial thromboembolic disease (eg, stroke, myocardial infarction)
  • Liver dysfunction or disease
  • Vivelle-Dot should not be used in patients with known hypersensitivity to its ingredients
  • Known or suspected pregnancy. There is no indication for Vivelle-Dot in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy

Download this information for your patients

Did you find this page helpful? Yes No

Vivelle-Dot has 4 Indications for Menopause

Vivelle-Dot, the #1 prescribed transdermal estrogen therapy, is FDA approved for 4 indications.
Learn more

Great Design with DOT Matrix® Technology

Delivery Optimized Thermodynamics (DOT) Matrix® Technology provides multiple benefits.
Learn more

Order Samples & Support Materials

Extensive patient support in and out of the office.
Learn more
  1. Vivelle-Dot (estradiol transdermal system) [prescribing information]. Novartis Pharmaceuticals Corporation; August 2004.
X
Tell A Colleague

Share information about Vivelle-Dot® by e-mailing this Web site to a colleague.

After clicking the "Send" button below, your colleague will receive an e-mail containing a link to this Web site.
* Required Fields
Leaving the Vivelle-Dot® Web Site